

4th Cuneo City ImmunoTherapy Conference (CCITC)

Immunotherapy in Hematological Malignancies 2024

October 10-12, 2024

**Spazio Incontri Fondazione CRC
CUNEO**



Organized by Prof. Massimo Massaia, SC Ematologia AO S.Croce e Carle, Cuneo - Italy and
Centro Interdipartimentale di Biotecnologie Molecolari "Guido Tarone" (MBC), Torino - Italy



SIE – Società Italiana di Ematologia



Immunotherapy in Hematological Malignancies 2024

October 10-11-12, 2024

CIRINO	BOTTA	Palermo, Italy	CHIARA	RUSCONI	Milano, Italy
BENEDETTO	BRUNO	Torino, Italy	DOMENICO	RUSSO	Brescia, Italy
CARMELO	CARLO-STELLA	Rozzano-MI, Italy	ELISA	SCARSELLI	Roma, Italy
GIULIA	CASORATI	Milano, Italy	MARTINA	SEIFFERT	Heidelberg, Germany
CLAUDIA	CASTELLINO	Cuneo, Italy	ROBERTO	SORASIO	Cuneo, Italy
VINCENZO	CERULLO	Helsinki, Finland	ALESSANDRA	TEDESCHI	Milano, Italy
ROBERTO	CHIARLE	Boston, USA; Milano-Torino, Italy	SARAH	TETTAMANTI	Monza-MB, Italy
FABIO	CICERI	Milano, Italy	LIVIO	TRANCHIDA	Cuneo, Italy
DANIELA	CILLONI	Torino, Italy	LUCA A.E.	VAGO	Milano, Italy
PAOLO	CORRADINI	Milano, Italy	UMBERTO	VITOLO	Candiolo-TO, Italy
ANTONIO	CURTI	Bologna, Italy			
MICHELE	DEL VECCHIO	Milano, Italy			
ENRICO	DERENZINI	Milano, Italy			
MASSIMO	DI NICOLA	Milano, Italy			
FRANCESCO	DI RAIMONDO	Catania, Italy			
HERMANN	EINSELE	Würzburg, Germany			
ROBERTO	FOA'	Roma, Italy			
GIANLUCA	GAIDANO	Novara, Italy			
MARIELLA	GRASSO	Cuneo, Italy			
MELANIE	HAGEN	Erlangen, Germany			
GIORGIO G.	INGHIRAMI	New York, USA			
LARRY	KWAK	Duarte, USA			
MARCO	LADETTO	Alessandria, Italy			
ROBERTO M.	LEMOLI	Genova, Italy			
MASSIMO	MASSAIA	Cuneo-Torino, Italy			
DANIELE	MATTEI	Cuneo, Italy			
FRANCESCO	MAURA	Miami, USA			
NICOLA	MORDINI	Cuneo, Italy			
LUIGI	NALDINI	Milano, Italy			
SATTVA S.	NEELAPU	Houston, USA			
CRISTINA	PAPAYANNIDIS	Bologna, Italy			
ALESSANDRO	RAMBALDI	Bergamo, Italy			
DAVIDE	RAPEZZI	Cuneo, Italy			
ANNA	RUBINO	Cuneo, Italy			
MARCO	RUELLA	Philadelphia, USA			

13:45 - 14:00	Welcome M. Massaia, L. Tranchida, A. Rubino
14:00 - 16:00	SESSION I Immunotherapy and targeted therapy in lymphoid malignancies I Chairmen: C. Castellino, U. Vitolo
14:00 - 14:20	News and views in indolent lymphomas E. Derenzini
14:20 - 14:30	Discussion
14:30 - 14:50	News and views in aggressive lymphomas C. Carlo-Stella
14:50 - 15:00	Discussion
15:00 - 15:20	News and views in Hodgkin lymphoma C. Rusconi
15:20 - 15:30	Discussion
15:30 - 15:50	News and views in acute lymphoblastic leukemia A. Rambaldi
15:50 - 16:00	Discussion
16:00 - 16:30	Coffee break

16:30 - 18:30	SESSION II Immunotherapy and targeted therapy in lymphoid malignancies II Chairmen: F. Di Raimondo, M. Grasso
16:30 - 16:50	News and views in chronic lymphocytic leukemia and Waldenström disease A. Tedeschi
16:50 - 17:00	Discussion
17:00 - 17:20	Tumor-host interactions as determinants of immunotherapy responses in CLL M. Seiffert
17:20 - 17:30	Discussion
17:30 - 17:50	Bispecific antibodies and CAR-T in multiple myeloma H. Einsele
17:50 - 18:00	Discussion
18:00 - 18:20	Genomic and immune predictors of immunotherapy responses in myeloma F. Maura
18:20 - 18:30	Discussion

09:30 - 11:00

SESSION III

Immunotherapy and targeted therapy in myeloid malignancies

Chairmen: R.M. Lemoli, D. Mattei

09:30 - 09:50

Current and future approaches: from AML to BPDCN

C. Papayannidis

09:50 - 10:00

Discussion

10:00 - 10:20

CAR-T in AML: ready for prime time?

S. Tettamanti

10:20 - 10:30

Discussion

10:30 - 10:50

Immune dysregulation and driver mutations in myeloid malignancies

A. Curti

10:50 - 11:00

Discussion

11:00 - 11:30

Coffee break

11:30 - 13:00

SESSION IV

Expanding CAR-T cell applications and efficacy

Chairmen: D. Rapezzi, D. Russo

11:30 - 11:50

CAR-T SIE: state of the art

P. Corradini

11:50 - 12:00

Discussion

12:00 - 12:20

Mechanisms of CAR-T resistance

M. Ruella

12:20 - 12:30

Discussion

12:30 - 12:50

CAR-T cell therapy in autoimmune diseases

M. Hagen

12:50 - 13:00

Discussion

13:00 - 14:00

Lunch

14:00 - 15:30	SESSION V Exploring innovative cell-therapy approaches I Chairmen: R. Foà, M. Ladetto
14:00 - 14:20	Editing of tumor microenvironment with targeted cell and gene therapy L. Naldini
14:20 - 14:30	Discussion
14:30 - 14:50	Allogeneic CAR-T cell therapy: mechanisms of expansion and rejection S.S. Neelapu
14:50 - 15:00	Discussion
15:00 - 15:20	Clinical results on decentrally manufactured CD19 CAR-T cells M. Massaia
15:20 - 15:30	Discussion
15:30 - 16:00	<i>Coffee break</i>

16:00 - 18:00	SESSION VI Exploring innovative cell-therapy approaches II Chairmen: D. Cilloni, G. Gaidano
16:00 - 16:20	NKT as alternative TCR/CAR-T cell platform G. Casorati
16:20 - 16:30	Discussion
16:30 - 16:50	Humanized mouse models as a predictive platform for adaptive immunotherapy G.G. Inghirami
16:50 - 17:00	Discussion
17:00 - 17:20	Personalized oncolytic virotherapy V. Cerullo
17:20 - 17:30	Discussion
17:30 - 17:50	An immune portfolio for ALK tumors: from vaccine to cellular immunotherapies R. Chiarle
17:50 - 18:00	Discussion

09:30 - 11:00 **SESSION VII**

Immunological hints from solid tumors

Chairmen: C. Botta, R. Sorasio

09:30 - 09:50 Discovery of new targets for CAR-T cells in solid tumors

M. Di Nicola

09:50 - 10:00 Discussion

10:00 - 10:20 Neoantigens based vaccines in cancer prevention

E. Scarselli

10:20 - 10:30 Discussion

10:30 - 10:50 Individualized neoantigenic therapy in melanoma

M. Del Vecchio

10:50 - 11:00 Discussion

11:00 - 11:30 *Coffee break*

11:30 - 13:00 **SESSION VIII**

Personalized immunotherapy: from allotransplant to targeted therapy

Chairmen: B. Bruno, N. Mordini

11:30 - 11:50 Allotransplant state of the art

F. Ciceri

11:50 - 12:00 Discussion

12:00 - 12:20 Mechanisms of relapse: differences and similarities with CAR-T cells

L.A.E. Vago

12:20 - 12:30 Discussion

12:30 - 12:50 Towards a personalized approach to immune therapies for cancer: one drug, one patient

L. Kwak

12:50 - 13:00 Discussion

13:00 - 13:10 Goodbyes and meeting close

M. Massaia

With an unrestricted educational grant of

Johnson & Johnson

 NOVARTIS

| abbvie

AstraZeneca 

 BeiGene

Lilly

Galápagos

 GILEAD |  Kite

 Pfizer
Oncology

sanofi

 sobi
rare strength

GENERAL INFORMATION

MEETING VENUE

Spazio Incontri Fondazione CRC
Via Roma, 15
12100 Cuneo - Italy

REGISTRATION

Registration is free and available at www.ercongressi.it
in the section "I nostri congressi/2024"

OFFICIAL LANGUAGE

English. No simultaneous translation is provided.

CME

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi Srl - ID 828 - 421934
- N. 9,1 CME for Physicians (disciplines: pathologic anatomy, hematology, infectious diseases, internal medicine, transfusion medicine, oncology, clinical pathology (chemical analysis laboratory and microbiology), radiotherapy), Chemists (other sector chemist, SSN public chemist, territorial chemist), Biologists, Biomedical laboratory health technician, Nurses
- Educational Objective: linee guida-protocolli-procedure

SCIENTIFIC SECRETARIAT

Massimo Massaia

SC Ematologia - AO S. Croce e Carle
Via Michele Coppino 26, 12100 Cuneo, Italy
Laboratorio di Immunologia dei Tumori del
Sangue (LITS)
Centro Interdipartimentale di Ricerca
in Biologia Molecolare (CIRBM)
Università degli Studi di Torino

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti 1/7 - 40124 Bologna, Italy
Phone +39 051 4210559
E-mail: ercongressi@ercongressi.it
www.ercongressi.it